Research INVESTMENTS

Dear Friend,

 

February 5th, 2013 Ross asked that our family promise not to let another child go through what he 

went through. 

On October 7th, 2013 we formally began the work of that promise. Today, with pride, we share the success of the Foundation with our thanks to you.

Our mission to end pediatric brain cancer includes two clear efforts: to fundraise for research and to increase awareness. R33M has channeled all of its momentum there with great accomplishments.

Thanks to your involvement, devotion and financial support our promise to fund the most innovative pediatric brain cancer research has arrived.

 

Imagine a child, diagnosed with a brain tumor, 

receiving a vaccine that will fight against their cancer.

Imagine research that generates

a humanized mouse model and identifies 

effective therapies against a brain tumor.

Imagine an investment that allows 16 institutions world-wide,

including more than 45 scientific projects, to accelerate solutions.

 

These three research investments are diverse, have high reward potential, and lead to successful, non-toxic treatments for children with brain tumors. We are thrilled to be the engine that supports this work moving forward.  

As you continue reading, you will see the amazing details of R33M’s work.

Enjoy, be proud, and know that you are a part of something significant.   

We hope you will remain close to R33M.

In humble gratitude,

 

Kim MacNeill

Co-Founder and President

Phase 1 Vaccine Trial

Ann & robert h. lurie children's hospital of chicago

Physician/Researcher

Jason Fangusaro, MD, Attending Physician

Ann & Robert H. Lurie Children’s Hospital of Chicago, IL

The goal of this trial is to have a vaccine that will boost the body’s immune system to fight against tumor growth or recurrence.This trial is scheduled to enroll patients this summer. We have established The Ross K. MacNeill Neuro-oncology Research Innovation Fund at Lurie Children’s to be the mechanism for this and ongoing investments in pediatric brain cancer research.  

 

Research Title: A Phase I and Feasibility Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Pediatric Patients with Newly Diagnosed Intracranial Resectable High Grade Glioma and Recurrent Resectable Intracranial High Grade Glioma and Recurrent Resectable Ependymoma

 

Type of Pediatric Brain Cancer: High-grade glioma and ependymoma tumors.

 

Research Goal: Our priority is to ensure this trial is safe and feasible in children with recurrent brain tumors. The project, which is based on Dr. Parsa’s work with a vaccine trial in adults, will be among the first to study the use of this specific method of developing vaccines in pediatric brain tumor patients.  If found safe and feasible, further studies will be undertaken to enroll more patients and test the vaccine’s efficacy.

Humanized models for Highest-Risk Medulloblastoma

university of California, San Francisco

Physician/Researcher

William A. Weiss, MD, PhD

University of California, San Francisco

Successful completion of this 3-year research will generate a humanized mouse model and establish the preclinical basis for a clinical trial in children with this incurable form of medulloblastoma.  

 

Research Title: Humanized models for highest-risk medulloblastoma

 

Type of Pediatric Brain Cancer: Highest-risk medulloblastoma

Research Goal: We hypothesize that MYCN cooperates with gain of GLI2 and with loss of p53 to drive medulloblastoma resistant to current standard therapies, and that modeling this highest-risk subtype of MB offers opportunities to identify effective therapies.  The goal of this research is to establish a human stem-cell based model for highest-risk medulloblastoma.  This model provides an in-vivo platform to identify targeted therapies for children with MCN/GL12/p53-driven medulloblastoma.  

children's brain tumor tissue consortium

children's hospital of philadelphia

16 National & International member institutions

 

Children's Hospital of Philadelphia

Seattle Children's

UPMC Children's Hospital of Pittsburgh

Ann & Robert H. Lurie Children's Hospital of Chicago

Benioff Children's Hospital (UCSF)

Lucile Packard Children's Hospital Stanford

Meyer Children's Hospital, Florence, Italy

Weill Cornell Medicine Pediatric Brain and Spine Center

Children's National Health System

Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center

Children's Hospital of Orange County

UCSC Treehouse Childhood Cancer Initiative

Beijing Tiantan Hospital Neurosurgery Center, Beijing, China

Dayton Children's Hospital

The Hudson Institute of Medical Research, Melbourne, Australia

Successful completion of this collaborative allows research to be expedited towards success because of shared data and open access to biospecimens.

 

Research: This collaborative allows all investigators within the 16 institutions open access to all research data and tumor specimens.

 

Type of Pediatric Brain Cancer: All pediatric brain cancer types.

Research Goal: The open access model provides researchers across the world biospecimens and data that may otherwise take years or decades to procure.  This leading-edge, first of it's kind, collaborative will accelerate research discovery to help children diagnosed with brain tumors.

At The Ross K. MacNeill Foundation our mission is to raise money for research and awareness for this diagnosis. R33M™ is currently investing in exciting research. Take a look & join us with your donation.

  • Facebook
  • Instagram
  • Twitter

The Ross K. MacNeill Foundation

333 N. Michigan Avenue

Suite 633

Chicago, IL  60601

info@R33M.org

The Ross K. MacNeill Foundation is a non-profit, tax-exempt public charity under section 501(c)(3) of the Internal Revenue Code.  EIN #46-3822276